NCT07895043: A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
- State
- Not started
- Phase
- Phase 2
- People
- 80 planned
- Started
- 20 Nov 2026
- Primary completion
- Dec 2031
- Arms
- ABBV-706 Dose A + Alveltamig + Atezolizumab, ABBV-706 Dose B + Alveltamig + Atezolizumab
- Results
- None posted
- 26 Oct 2026: Trial registered